Perinatal Depression: Preventive Interventions
February 12, 2019
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
By Elizabeth O’Connor, PhD; Caitlyn A. Senger, MPH; Michelle L. Henninger, PhD; Erin Coppola, MPH; and Bradley N. Gaynes, MD, MPH
The information in this article is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This article is intended as a reference and not as a substitute for clinical judgment.
This article may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
This article was first published in JAMA on February 12, 2019.
Importance: Depression during pregnancy and the postpartum period is relatively common and can have adverse effects on both mother and child.
Objective: To systematically review benefits and harms of primary care–relevant interventions to prevent perinatal depression, a major or minor depressive episode during pregnancy or up to 1 year after childbirth, to inform the US Preventive Services Task Force.
Data Sources: MEDLINE, PubMED (for publisher-supplied records only), PsycINFO, and the Cochrane Central Register of Controlled Trials; surveillance through December 5, 2018.
Study Selection: Randomized clinical trials (RCTs) and nonrandomized controlled intervention studies of interventions (eg, behavior-based, antidepressants, dietary supplements) to prevent perinatal depression in general populations of pregnant and postpartum individuals or in those at increased risk of perinatal depression. Large cohort studies were considered for harms of antidepressant use only.
Data Extraction and Synthesis: Two investigators independently reviewed abstracts and full-text articles and quality rated included studies. Random-effects meta-analysis was used to estimate the benefits of the interventions.
Main Outcomes and Measures: Depression status; depression symptoms; maternal, infant, and child health outcomes.
Results: Fifty studies (N = 22,385) that met inclusion criteria were identified. Counseling interventions were the most widely studied interventions. Compared with controls, counseling interventions were associated with a lower likelihood of onset of perinatal depression (pooled risk ratio [RR], 0.61 [95% CI, 0.47-0.78]; 17 RCTs [n = 3094]; I2 = 39.0%). The absolute difference in the risk of perinatal depression ranged from 1.3% greater reduction in the control group to 31.8% greater reduction in the intervention group. Health system interventions showed a benefit in 3 studies (n = 5321) and had a pooled effect size similar to that of the counseling interventions, but the pooled effect was not statistically significant using a method appropriate for pooling a small number of studies (restricted maximum likelihood RR, 0.58 [95% CI, 0.22-1.53]; n = 4738; I2 = 66.3%; absolute risk reduction range, −3.1% to −13.1%). None of the behavior-based interventions reported on harms directly. A smaller percentage of participants prescribed sertraline had a depression recurrence compared with those prescribed placebo (7% vs 50%, P = 0.04) at 20 weeks postpartum in 1 very small RCT (n = 22 analyzed) but with an increased risk of adverse effects to the mother.
Conclusions and Relevance: Counseling interventions can be effective in preventing perinatal depression, although most evidence was limited to women at increased risk for perinatal depression. A variety of other intervention approaches provided some evidence of effectiveness but lacked a robust evidence base and need further research.
Perinatal depression is a common condition that was estimated in 2012 to affect more than 180,000 new mothers (11.5%) annually in the United States and that can have a devastating effect on the mother as well as the infant.1 Perinatal depression is defined as the occurrence of a major or minor depressive episode during pregnancy or up to 1 year after childbirth.2 In addition to the typical symptoms of depressive disorders (eg, feeling hopeless, loss of interest in activities that used to be enjoyed, withdrawing from friends and family), other symptoms in the perinatal period may include persistent doubt of the ability to take care of the infant, trouble bonding with the infant, and thoughts of self-harm or harm of the infant.3
Risk factors that can be used to identify individuals at risk for perinatal depression include a history of depression,4-7 history of physical or sexual abuse,5 unplanned or unwanted pregnancy,8 stressful life events,1,5,9 intimate partner violence,10,11 and complications during pregnancy.12 Additionally, low socioeconomic status, lack of social support, and bearing children during adolescence have been associated with a greater risk of developing perinatal depression after delivery.5,6,8,13 Numerous interventions have been proposed to prevent perinatal depression; however, there is no commonly agreed-on method of prevention. Thus, there is likely substantial variation in clinical practice. Although there are risk factors for perinatal depression and interventions exist that may help prevent perinatal depression, the effectiveness of these interventions and the subpopulations who could most benefit need further evaluation.
There are currently no clinical guidelines on how to prevent perinatal depression and no prior US Preventive Services Task Force (USPSTF) recommendation on this topic. This systematic review was conducted to synthesize the evidence related to the effectiveness of interventions in preventing perinatal depression to support a new USPSTF recommendation.
The USPSTF commissioned this review to evaluate direct evidence from trials and large cohort studies (for harms of antidepressant use only) on interventions to reduce the risk of perinatal depression initiated during pregnancy or the first year postpartum. Specifically, the 2 key questions (KQs) (Figure 1) aimed to identify the benefits (KQ1) and harms (KQ2) of interventions to prevent perinatal depression for pregnant or postpartum individuals and their children. Additional methodological details regarding the review search strategies, detailed study inclusion criteria, quality assessment, excluded studies, and description of data analyses are publicly available in the full evidence report at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/perinatal-depression-preventive-interventions.
Data Sources and Searches
Comprehensive literature searches were performed for primary literature in MEDLINE, PubMed (for publisher-supplied records only), PsycINFO, and the Cochrane Collaboration Registry of Controlled Trials from January 2012 through February 6, 2018. Database searches were supplemented with suggestions from preidentified experts in the field and by reviewing reference lists from other relevant systematic reviews. After February 2018, ongoing surveillance continued through article alerts and targeted searches of high-impact journals to identify major studies published in the interim that could affect the conclusions or understanding of the evidence and affect the related USPSTF recommendation. The last surveillance was conducted on December 5, 2018, and resulted in the addition of no new studies.
Two reviewers independently reviewed abstracts and full-text articles against specified inclusion criteria (Figure 2). Studies were eligible if they were published in English, conducted in countries ranked as having “very high” human development according to the World Health Organization, and included pregnant persons or mothers up to a maximum of 1 year postpartum. Studies limited to persons with mental health symptoms or disorders (eg, anxiety disorders) were eligible; however, studies limited to perinatal individuals currently experiencing or being treated for a depressive episode were excluded, as were studies limited to persons with psychotic or developmental disorders. In addition, studies limited to persons with a medical condition (eg, HIV/AIDS), and those limited to persons in institutions (eg, psychiatric inpatients) or long-term care or residential facilities were excluded because of generalizability concerns. Studies that included a subset of these types of participants were included; however, it was required that the number not exceed 50% of the total sample to be considered for inclusion.
Studies were required to have a primary or secondary aim to prevent perinatal depression. The following interventions were included: counseling (eg, cognitive-behavioral therapy [CBT], interpersonal therapy [IPT]), psychoeducation, or other supportive interventions (eg, peer mentoring); care delivery models targeting improved mental health outcomes; prophylactic use of antidepressants; widely available physical activity or complementary and alternative therapies;and hormonal therapy. Pharmacotherapy harms were only to be evaluated for medications that were found to support the prevention of perinatal depression and were to be examined only during the phase (pregnancy or postpartum) in which the evidence was identified. Interventions composed of general parenting education without a mental health component (eg, prenatal or infant care classes) were excluded.
Depression diagnosis (determined through a clinical interview) or symptoms (measured using a validated instrument) were a required outcome for included studies. Other maternal health outcomes, infant and child outcomes, birth outcomes, and any information reported on harms were also abstracted. Relevant outcomes reported at least 6 weeks after the baseline assessment or intervention initiation were included, although harms outcomes reported any time after the intervention was initiated were considered.
Interventions that were conducted in or recruited from primary care or a health care system, or that could potentially be implemented in or referred from primary care, were included. This included interventions taking place in primary care clinics; prenatal clinics; obstetrics/gynecology clinics; pediatric clinics; family planning clinics; military health clinics; school-based health clinics; mental health clinics; and research settings, homes, or other community settings, including electronic or computer-based interventions. Studies conducted in correctional facilities, school classrooms, worksites, and emergency departments were excluded.
Data Extraction and Quality Assessment
Two reviewers applied USPSTF design-specific criteria14 to assess the methodological quality of all eligible studies. Each study was assigned a quality rating of “good,” “fair,” or “poor.” Discordant quality ratings were resolved by discussion or by a third reviewer and adjudicated as needed. Studies were rated as poor quality and excluded if there was a major flaw such as very high attrition (generally >40%),differential attrition between intervention groups (generally >20%); substantial lack of baseline comparability between groups without adjustment; or major concerns about the trial conduct, analysis, or reporting of results. One investigator extracted study-level data using data entry forms developed in DistillerSR (Evidence Partners) and a second investigator confirmed the accuracy of the data.
Data Synthesis and Analysis
Summary tables showing study, population, intervention characteristics, and outcomes were created. Studies were examined overall and grouped according to intervention type: counseling, health system, physical activity, education (without counseling, extensive skills practice, or other supportive interventions), support (without counseling or skill-building), infant sleep, debriefing (exploring the events and emotions of the birth experience, with a counselor providing normalization and education), other behavior-based approaches, antidepressants, and supplements. The intervention categories were developed post hoc, and some trials were difficult to categorize and could possibly have fit into more than 1 category. The one that appeared to have the best fit was chosen by the primary investigator.
Because of its clinical utility, depression status was chosen as the primary outcome. Most trials reported a related dichotomous depression outcome: cumulative incidence of depression, prevalence, or the proportion scoring above a cutoff on a symptom severity scale. Since most trials excluded women with depression or high symptom levels at baseline, it was assumed that most cases of depression identified after the start of the study would be new-onset cases, but not necessarily first-onset cases, since many women had previous episodes of depression.
Strength of evidence was rated for each key question, based on consistency (similarity of effect direction and size), precision (degree of certainty around an estimate), reporting bias (potential for bias related to publication, selective outcome reporting, or selective analysis reporting), and study quality (ie, study limitations).
Random-effects models on both the main outcome of depression status and continuous measures of depression symptom severity were conducted, both overall and separately by intervention. The DerSimonian and Laird model for pooling was used, and I2 and Q statistic were calculated to test for heterogeneity. In addition, because the DerSimonian and Laird method is prone to insufficient coverage of the full 95% confidence intervals when the number of studies is small and statistical heterogeneity is high, restricted maximum likelihood models with the Knapp-Hartung correction for small samples were used when fewer than 10 trials were pooled and the DerSimonian and Laird model showed a statistically significant effect. For the full body of evidence, a funnel plot was generated and the Egger test was performed to explore small-study effects, which can be related to publication bias.15 Additionally, meta-regression and sensitivity analyses were conducted to explore factors associated with effect size for the dichotomous depression status outcome.
Stata version 15.1 (StataCorp LP) was used for all analyses. All significance testing was 2-sided, and results were considered statistically significant if the P value was 0.05 or less.
Two reviewers independently assessed 1036 abstracts and reviewed 247 full-text articles. In total, 50 studies (8 good quality, 42 fair quality; N = 22,385; 49 randomized clinical trials [RCTs]16-64 and 1 nonrandomized controlled intervention study65) were included (Figure 2; eTable 1 in the Supplement). Of the 50 included studies, 20 (40%) were conducted in the United States, and most recruited women from primary care or obstetrics/gynecology practices (33/50 [66%]) or from other clinical settings (13/50 [26%]) such as in the hospital postdelivery, through electronic medical records, or in clinic- or hospital-based childbirth education classes (Table 1). Twenty-six of the included studies (52%) recruited pregnant women, 22 (44%) recruited postpartum women, and 2 (4%) recruited women who were pregnant as well as those up to 26 weeks postpartum.16,17 Most studies (42/50 [84%]) were limited to women 18 years or older, but 1 was limited to adolescents18 and 7 had no age restrictions.19-25 The studies assessed the effect of a wide range of intervention approaches, including counseling, health system–level interventions, physical activity, supportive interventions, education, infant sleep advice, birth-experience postpartum debriefing, expressive writing, yoga, omega-3 fatty acids, sertraline, and nortriptyline. For all KQs, additional descriptive and outcome data are available in the full report.
Twenty-seven studies (54%) selected women at increased risk for perinatal depression, such as having a personal or family history of depression (or perinatal depression), elevated depressive symptoms, or socioeconomic (eg, low income, single, young, recent intimate partner violence) or mental health (eg, elevated anxiety symptoms) risk factors (Table 1). The most common approach was to select women on the basis of depression symptoms or history.16,17,26-35 The Edinburgh Postnatal Depression Scale (EPDS; range, 0-30; higher score indicates greater distress) and the Center for Epidemiologic Studies Depression Scale (CES-D; range, 0-60; higher score indicates greater distress) were the most widely used tools for identifying women at risk for developing postpartum depression in the included studies.
Although the majority of participants in the included studies were non-Hispanic white (69% of all participants in trials that reported race/ethnicity), 2 trials were limited to Latina women,27,28 and 8 had majority black and Latina samples.16-18,36-40 In addition, 13 studies (26%) were primarily or entirely composed of economically disadvantaged women.16,17,22,27,28,37-44
Benefits of Preventive Interventions
Key Question 1. Do interventions to prevent perinatal depression improve health outcomes in pregnant or postpartum women or their children?
Key Question 1a. In trials that limit enrollment to high-risk women, how are participants identified as being at high risk of developing perinatal depression?
Twenty RCTs (2 good quality, 18 fair quality) of counseling interventions were identified (n = 4107). Seventeen of these reported incidence, prevalence, and exceeding symptom cutoff and are included in this pooled estimate; the 3 studies43,45,46 that did not report these dichotomous measures all reported continuous measures of depressive symptoms, with mixed findings. The pooled risk ratio (RR) for counseling interventions was 0.61 when the outcomes of incidence, prevalence, and exceeding symptom cutoff were combined (95% CI, 0.47 to 0.78; 17 trials [n = 3094]; I2 = 39.0%) (Figure 3). The proportion of participants with depression according to any of the dichotomous depression outcomes at the main time point of 26 weeks postpartum (or the closest to this time point) ranged from 0% to 34% in the intervention groups, compared with 6% to 50% in the control groups, with absolute risk differences (ARDs) ranging from 1.3% greater reduction in the control group to 31.8% greater reduction in the intervention group. Of these 17 trials, 13 (76%) reported an outcome of major depressive disorder diagnosis based on a clinical interview. Trials reported depression outcomes over a wide range of follow-up time points, ranging from 6 to 52 weeks postpartum.
Effects were largest for CBT- and IPT-based interventions (Table 2), and the 2 most commonly used approaches were the CBT-based Mothers and Babies program (used in 4 studies16,17,27,28) and the IPT-based Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program (used in 5 studies18,37-40). The Mothers and Babies program involved 8 to 17 group sessions during pregnancy and postpartum, with a goal of helping participants create a healthy physical, social, and psychological environment for themselves and their infants. The ROSE program involved 4 to 6 sessions during pregnancy and postpartum, covering topics such as stress management, development of a social support system, role transitions and changes associated with role transitions, and types of interpersonal conflicts common around childbirth.
When limited to trials that only included women at increased risk of perinatal depression, the pooled RR was 0.55 (95% CI, 0.44 to 0.68; 14 trials [n = 1411]; I2 = 0%) (Table 2). There was a statistically significant small-studies effect for the counseling trials (Egger test, −1.52; P = 0.01). Smaller trials were more likely to limit inclusion to populations selected for increased risk of perinatal depression, which may have been a major source of the association between effect size and study size.
Overall, counseling interventions were associated with a small beneficial effect in symptom score measures, amounting to a pooled standardized effect size of 0.2, which would generally be considered a small effect,66 or a 1.5-point greater reduction in depression symptom severity than control conditions (standardized mean difference, −0.21 [95% CI, −0.40 to −0.02]; 13 trials [n = 1367]; I2 = 57.2%); weighted mean difference in change between groups, −1.51 [95% CI, −2.84 to −0.18]; 13 trials [n = 1367]; I2 = 61.3%). This analysis combined a variety of instruments with 30- to 63-point ranges. Thirteen trials reported continuous symptom score measures and showed a wide range of results; however, group differences were statistically significant in only 5 trials.16,17,29,37,42
Most of the counseling trials also reported other maternal or child outcomes; however, there was a wide variety of outcome measures and little consistency across studies. Stress and anxiety were the most commonly reported other maternal or child outcome. For example, 4 trials42,46-48 reported a measure of stress, but most did not show statistically or clinically important differences between groups. Other outcomes, generally reported by only 1 or 2 studies, included measures of functioning (general,19,38 maternal,21 and family21,42,48), quality of life,48 social support,16,42 trauma symptoms,39 mental health treatment,40 breastfeeding,38 child development,49 child attachment,49 birth weight,42 and preterm birth.42 Of these, 1 trial (n = 184) showed statistically significant benefits on birth weight (between-group difference, 283 g; P = 0.01) and incidence of preterm birth (RR, 0.19 [95% CI, 0.06 to 0.65]).42 No other outcomes were statistically significant.
Fifteen of the 20 trials of counseling interventions (75%) were limited to women who were known to be at increased risk of perinatal depression, owing to depression history or symptoms (6/20 [30%]), non–depression-related risk factors (3/20 [15%]), or either depression-related or other risk factors (6/20 [30%]). Thirteen of the 20 trials (65%) excluded women who met diagnostic criteria for current major depression or scored above a prespecified cutoff on a symptom severity scale. The trials that did not exclude women with a depression diagnosis or high symptom level used either unselected populations or selected participants based on non–depression-related criteria, so the proportion with depression was estimated or reported to be well below 50%.
Counseling interventions lasted a median of 8 weeks (range, 4-70 weeks), included a median of 8 sessions (range, 4-20 sessions), and had an estimated median of 12 hours of contact (range, 4-23.3 hours). Fifteen (75%) included group sessions, 11 (55%) included individual sessions, and 3 intervened with couples.19,45,50 Most of the interventions used CBT or IPT approaches. Information on adherence for counseling and other intervention approaches is available in the full evidence report.
Health System Interventions
Three fair-quality studies (n = 5321; 2 RCTs,23,51 1 nonrandomized controlled intervention study65) examined the effects of health system–level interventions. All 3 programs showed beneficial effects on depression, with RRs ranging from 0.33 (95% CI, 0.19 to 0.58; n = 433; ARD, −13.1%) to 0.71 (95% CI, 0.53 to 0.95; n = 2241; ARD, −3.1%) for exceeding a specified depression symptom level at follow-up. The pooled RR for health system interventions was 0.60 (95% CI, 0.43 to 0.83; 3 studies [n = 4738]; I2 = 66.3%) (Figure 3). However, this association was not statistically significant with the restricted maximum likelihood analysis, which better accounts for the small number of studies pooled (RR, 0.58 [95% CI, 0.22 to 1.53]). None were conducted in the United States, so applicability to this country may be limited. Additionally, none limited their sample to women at increased risk of depression, suggesting that some universal prevention programs may be effective.
Health outcomes were sparsely reported in these studies and showed mixed results (see full evidence report for more details). No infant or child outcomes were reported in these trials.
Other Intervention Approaches
A wide variety of other intervention approaches were identified. Some of these approaches showed benefit in some trials, but most trials did not find statistically significant group differences (Figure 4, for studies reporting sufficient data to plot). The intervention focus of these studies included physical activity (3 RCTs [n = 1200]),52-54 education (without counseling or extensive support; 6 RCTs [n = 2949]),20,30,41,55-57 supportive interventions (without formal counseling; 7 RCTs [n = 4569]),22,24,31,44,58,59 infant sleep advice (3 RCTs [n = 980]),36,60,61 birth-experience postpartum debriefing (2 RCTs [n = 2786]),25,62 expressive writing (1 RCT [n = 120]),63 antidepressants (2 RCTs [n = 80]),33,34 supplements (2 RCTs [n = 227]),35,64 and yoga (1 RCT [n = 46]).26
Of these approaches, the physical activity interventions consistently reported point estimates in the direction of benefit (ARDs ranged from −1.3% to −12.5%), but only 1 trial found statistically significant group differences.53 Birth-experience debriefing25,62 and omega-3 fatty acid supplementation35,64 showed no benefit (study RRs ranged from 0.99 [95% CI, 0.87 to 1.11] [n = 1745] to 2.70 [95% CI, 0.56 to 13.09] [n = 79]). Additional sensitivity and subgroup analyses exploring effect sizes by study and intervention characteristics are available in the full report.
The 2 trials of antidepressants to prevent perinatal depression assessed the effects of nortriptyline (n = 58)33 and sertraline (n = 22).34 Both trials were conducted in the United States. The trial of nortriptyline found that the drug offered no preventive benefits compared with placebo (Figure 4).33 Neither the rates of recurrence between participants taking nortriptyline and those taking placebo (23% vs 24%; between-group statistics not reported; P > 0.99), nor the time to postpartum recurrence (detailed findings not reported; exact log-rank ≤0.00; P = 0.83) differed between the 2 groups. The trial of sertraline found that a smaller percentage of participants taking sertraline had a depression recurrence compared with those taking placebo (7% vs 50%; difference in recurrence rates, 0.43 [95% exact CI, −0.01 to 0.84]; P = 0.04) at 20 weeks postpartum.34 Further, the time to recurrence was faster in those receiving placebo (hazard ratio, 0.11 [95% exact CI, 0.02 to 1.02]; exact Wilcoxon-Gehan P = 0.02). In these trials, women with a history of postpartum depression in the previous 5 years were randomized to receive either an antidepressant (nortriptyline [75 mg/d]33 or sertraline [50 mg/d]34) or placebo for 17 weeks, starting as soon as possible after birth, followed by a 3-week tapering phase. Neither trial of antidepressants reported other maternal health outcomes or child outcomes.
Harms of Preventive Interventions
Key Question 2. What harms are associated with interventions to prevent perinatal depression in pregnant or postpartum women?
None of the nonpharmaceutical studies reported any global harms outcomes for either mothers or infants. Across all of these studies, none of the outcomes reported showed any pattern of increased risk of harms, based on group means.
Both antidepressant trials systematically collected adverse event information. In the nortriptyline trial (n = 58),33 the authors stated that participants tolerated nortriptyline well, reporting no differences in withdrawals attributable to adverse effects, with only 1 person withdrawing from each group. They reported only the number of events for 1 of the 11 adverse effects collected; constipation differed between groups (78% of the women taking nortriptyline vs 22% taking placebo). In the sertraline trial (n = 22),34 participants receiving sertraline were more likely than those receiving placebo to report dizziness (57% vs 13%, P = 0.05) and drowsiness (100% vs 50%, P = 0.02) but did not differ in rates of other adverse events (but data were not shown). Three women stopped taking sertraline because of adverse effects (21%), compared with none in the control group; however, this difference was not statistically significant. One participant taking nortriptyline and 1 taking sertraline converted to mania or hypomania, while no women taking a placebo did so; this difference was not statistically significant for either agent, although the studies were not powered for this outcome. There were no additional studies that addressed harms of sertraline in postpartum women. Additional harms studies of nortriptyline were not searched for because efficacy was not demonstrated for this treatment in the included studies.
No harms were associated with omega-3 fatty acids, although reports of adverse events were collected spontaneously rather than systematically through a validated instrument and adherence was by self-report. No significant differences in the proportion of participants reporting gastrointestinal adverse effects or adherence with the recommended intervention were reported.
The summary of evidence is reported in Table 3. This review found that counseling-based interventions, in particular depression-focused CBT and IPT, may be effective in preventing perinatal depression. This evidence was primarily limited to women at increased risk for perinatal depression, such as having current depressive symptoms, a history of depression, low socioeconomic status, and lack of support. The pooled RR of 0.61 for perinatal depression at up to 6 months postpartum for counseling interventions corresponds to a number needed to treat of 13.5 (95% CI, 9.9 to 23.9), assuming a 19% baseline risk of developing perinatal depression. Three different health system–level interventions were also effective in health care settings outside the United States, suggesting that similar interventions developed in US-based health care systems may have the potential to be effective and were not limited to women at increased risk of perinatal depression. In all 3 cases, usual care included home visitation, which may be a valuable intervention, suggesting the potential for even greater benefit compared with usual care in the United States. Additionally, other intervention approaches, such as physical activity or educational approaches, reported some positive findings but lacked robust evidence bases.
Only 2 studies of prophylactic use of antidepressants were identified, showing mixed results. Antidepressants can be an important tool for treatment of depression but have been associated with a number of rare but serious adverse events, including suicidality (in young adults), hyponatremia, seizures, gastrointestinal tract bleeding, and serotonin syndrome.67,68 The decision to use antidepressants in pregnant persons is complicated and is addressed by only a limited amount of evidence. The use of second-generation antidepressants during pregnancy has been associated with a small but increased risk of a number of serious pregnancy and neonatal outcomes.69 However, the clinical significance of these increased risks is unclear70 and most guidelines recommend antidepressants for severe depression, with a preference for sertraline,71 especially for those breastfeeding.72
The findings of this review are similar to those reported in other similarly scoped reviews. A 2013 review on psychosocial and psychological interventions to prevent perinatal depression found that women who received a psychosocial intervention were 22% less likely to develop perinatal depression, compared with usual care (pooled RR, 0.78 [95% CI, 0.66 to 0.93]; 20 studies [n = 14,727]).73 Another review of interventions designed to prevent perinatal depression found a pooled odds ratio of 0.67 for depressive episodes by 6 months postpartum, after excluding outliers (95% CI, 0.52 to 0.85; 26 studies; I2 = 46%).74 That review found no study or intervention characteristic that showed a statistically significant association with effect size.
An ideal method for determining which interventions would benefit persons with varying risk profiles is lacking, but the most common approach in the included trials was to include women with a history of depression or current depressive symptoms as measured by instruments such as the EPDS or CES-D. One study investigating the accuracy of the EPDS to predict future perinatal depression found that a cutoff of 9 or higher at 3 to 5 days postpartum had 82% sensitivity, 95% specificity, and a 43% positive predictive value for a diagnosis of major or minor depression at 8 weeks postpartum.75 The literature on predicting future perinatal depression includes a variety of patient- and clinician-administered tools, but results have been modest in many cases and need to be replicated.
There were a number of limitations in the studies underlying this review. There were relatively few good-quality trials, and approximately one-third of the trials within the scope of this review were excluded because of their poor quality. Many of these appeared to be pilot studies not designed to provide data on effectiveness of the intervention or that used intervention approaches that proved infeasible or ineffective and so were abandoned in the form studied. Some of these studies, however, could have provided useful information had they been conducted and reported in such a way that they met USPSTF quality standards.
The health system–level interventions in this review had limited applicability to health systems in the United States, especially since they involved enhancing home-visiting services, which are not routinely available in the United States. However, some home-visiting services are available in the United States, and these interventions also included other elements that would be relevant to US-based settings. Interventions designed for implementation in health care systems could involve clinician training, electronic medical records–based tools, and facilitated access to behavioral health specialists embedded in the primary care settings.
Another limitation of the evidence was the small number of trials examining several potentially valuable interventions, such as physical activity, infant sleep education, in-hospital perinatal depression education with follow-up, and peer counseling. In addition, larger-scale effectiveness trials of CBT and IPT approaches are needed to explore the degree to which these interventions can be scaled up, as well as their applicability to lower-risk, more general primary care populations. More research is also needed on the use of antidepressants and dietary supplements in the role of preventing perinatal depression.
Another important deficit in the literature is a lack of good information on the best way to identify individuals at risk for perinatal depression. Measures of depression symptoms, such as the EPDS, likely provide the most direct association with future perinatal depression. However, evidence is lacking on whether and how to incorporate other risk factors, as well as on who is most likely to benefit from preventive interventions and how those individuals are best identified.
The review has several limitations. First, it was challenging to determine whether prevention of perinatal depression was truly an a priori aim; it is possible that some studies were missed that had depression as a specific aim, and some studies may have been included that added the depression prevention aim post hoc after determining that their intervention was effective in preventing depression. Second, both the overall body of evidence and the counseling intervention trials had statistically significant small-studies effects. Smaller trials also tended to use interventions that more directly addressed depression and to offer more intensive interventions, so the small-studies effect may be influenced by these and other study characteristics. However, it could not be determined to what extent the effect might be biasing results and overestimating the effect sizes.
Counseling-based interventions can be effective in preventing perinatal depression, although most evidence was limited to women at increased risk for perinatal depression. A variety of other intervention approaches provided some evidence of effectiveness but lacked a robust evidence base and need further research.
Source: This article was first published in JAMA on February 12, 2019 (JAMA. 2019;321(6):388-601).
Conflict of Interest Disclosures: Dr Henninger reported receiving grants from Pfizer IGLC outside the submitted work. Dr Gaynes reported receiving personal fees from LivaNova and personal fees from Johnson and Johnson outside the submitted work. No other authors reported disclosures.
Funding/Support: This research was funded under contract number HHSA-290-2015-00017-I, Task Order 3, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.
Role of the Funder/Sponsor: Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study selection, quality assessment, or synthesis. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. Otherwise, AHRQ had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript findings. The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or the US Department of Health and Human Services.
Additional Information: A draft version of this evidence report underwent external peer review from 3 content experts (Sherryl Goodman, PhD, Emory University; Michael O’Hara, PhD, University of Iowa; Barbara Yawn, MD, University of Minnesota) and 1 federal partner: the Centers for Disease Control and Prevention. Comments from reviewers were presented to the USPSTF during its deliberation of the evidence and were considered in preparing the final evidence review.
1. Ko JY, Rockhill KM, Tong VT, Morrow B, Farr SL. Trends in postpartum depressive symptoms—27 states, 2004, 2008, and 2012. MMWR Morb Mortal Wkly Rep. 2017;66(6):153-158. doi:10.15585/mmwr.mm6606a1
2. Committee on Obstetric Practice. The American College of Obstetricians and Gynecologists Committee Opinion No. 630: screening for perinatal depression. Obstet Gynecol. 2015;125(5):1268-1271. doi:10.1097/01.AOG.0000465192.34779.dc
3. Fitelson E, Kim S, Baker AS, Leight K. Treatment of postpartum depression: clinical, psychological and pharmacological options. Int J Womens Health. 2010;3:1-14.
4. Bernazzani O, Saucier JF, David H, Borgeat F. Psychosocial predictors of depressive symptomatology level in postpartum women. J Affect Disord. 1997;46(1):39-49. doi:10.1016/S0165-0327(97)00077-3
5. Wilson LM, Reid AJ, Midmer DK, Biringer A, Carroll JC, Stewart DE. Antenatal psychosocial risk factors associated with adverse postpartum family outcomes. CMAJ. 1996;154(6):785-799.
6. Myers ER, Aubuchon-Endsley N, Bastian LA, Gierisch J, Kemper AR, Swamy GK, Wald MF, McBroom AJ, Lallinger KR, Gray RN, Green C, Sanders GD. Efficacy and Safety of Screening for Postpartum Depression. Rockville, MD: Agency for Healthcare Research and Quality; 2013. AHRQ publication 13-EHC064-EF.
7. Da Costa D, Larouche J, Dritsa M, Brender W. Psychosocial correlates of prepartum and postpartum depressed mood. J Affect Disord. 2000;59(1):31-40. doi:10.1016/S0165-0327(99)00128-7
8. Beck CT. Predictors of postpartum depression: an update. Nurs Res. 2001;50(5):275-285. doi:10.1097/00006199-200109000-00004
9. Venkatesh KK, Phipps MG, Triche EW, Zlotnick C. The relationship between parental stress and postpartum depression among adolescent mothers enrolled in a randomized controlled prevention trial. Matern Child Health J. 2014;18(6):1532-1539. doi:10.1007/s10995-013-1394-7
10. Kornfeld BD, Bair-Merritt MH, Frosch E, Solomon BS. Postpartum depression and intimate partner violence in urban mothers: co-occurrence and child healthcare utilization. J Pediatr. 2012;161(2):348-353.e2. doi:10.1016/j.jpeds.2012.01.047
11. Wu Q, Chen HL, Xu XJ. Violence as a risk factor for postpartum depression in mothers: a meta-analysis. Arch Women Ment Health. 2012;15(2):107-114. doi:10.1007/s00737-011-0248-9
12. Josefsson A, Angelsiöö L, Berg G, et al. Obstetric, somatic, and demographic risk factors for postpartum depressive symptoms. Obstet Gynecol. 2002;99(2):223-228.
13. Kim S, Soeken TA, Cromer SJ, Martinez SR, Hardy LR, Strathearn L. Oxytocin and postpartum depression: delivering on what’s known and what’s not. Brain Res. 2014;1580:219-232. doi:10.1016/j.brainres.2013.11.009
14. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. Rockville, MD: US Preventive Services Task Force; 2015.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629
16. Tandon SD, Leis JA, Mendelson T, Perry DF, Kemp K. Six-month outcomes from a randomized controlled trial to prevent perinatal depression in low-income home visiting clients. Matern Child Health J. 2014;18(4):873-881. doi:10.1007/s10995-013-1313-y
17. Tandon SD, Perry DF, Mendelson T, Kemp K, Leis JA. Preventing perinatal depression in low-income home visiting clients: a randomized controlled trial. J Consult Clin Psychol. 2011;79(5):707-712. doi:10.1037/a0024895
18. Phipps MG, Raker CA, Ware CF, Zlotnick C. Randomized controlled trial to prevent postpartum depression in adolescent mothers. Am J Obstet Gynecol. 2013;208(3):192.e1-192.e6. doi:10.1016/j.ajog.2012.12.036
19. Brugha TS, Wheatley S, Taub NA, et al. Pragmatic randomized trial of antenatal intervention to prevent post-natal depression by reducing psychosocial risk factors. Psychol Med. 2000;30(6):1273-1281. doi:10.1017/S0033291799002937
20. Fisher J, Rowe H, Wynter K, et al. Gender-informed, psychoeducational programme for couples to prevent postnatal common mental disorders among primiparous women: cluster randomised controlled trial. BMJ Open. 2016;6(3):e009396. doi:10.1136/bmjopen-2015-009396
21. Gorman L. Prevention of Postpartum Difficulties in a High Risk Sample [dissertation]. Iowa City, IA: University of Iowa; 1997.
22. Kenyon S, Jolly K, Hemming K, et al. Lay support for pregnant women with social risk: a randomised controlled trial. BMJ Open. 2016;6(3):e009203. doi:10.1136/bmjopen-2015-009203
23. MacArthur C, Winter HR, Bick DE, et al. Effects of redesigned community postnatal care on womens’ health 4 months after birth: a cluster randomised controlled trial. Lancet. 2002;359(9304):378-385. doi:10.1016/S0140-6736(02)07596-7
24. Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A. Costs and effectiveness of community postnatal support workers: randomised controlled trial. BMJ. 2000;321(7261):593-598. doi:10.1136/bmj.321.7261.593
25. Small R, Lumley J, Donohue L, Potter A, Waldenström U. Randomised controlled trial of midwife led debriefing to reduce maternal depression after operative childbirth. BMJ. 2000;321(7268):1043-1047. doi:10.1136/bmj.321.7268.1043
26. Davis K, Goodman SH, Leiferman J, Taylor M, Dimidjian S. A randomized controlled trial of yoga for pregnant women with symptoms of depression and anxiety. Complement Ther Clin Pract. 2015;21(3):166-172. doi:10.1016/j.ctcp.2015.06.005
27. Le HN, Perry DF, Stuart EA. Randomized controlled trial of a preventive intervention for perinatal depression in high-risk Latinas. J Consult Clin Psychol. 2011;79(2):135-141. doi:10.1037/a0022492
28. Muñoz RF, Le HN, Ippen CG, Diaz M, Urzar G, Soto J. Prevention of postpartum depression in low-income women: development of the Mamás y Bebés/Mothers and Babies course. Cognit Behav Pract. 2007;14(1):70-83. doi:10.1016/j.cbpra.2006.04.021
29. Dimidjian S, Goodman SH, Felder JN, Gallop R, Brown AP, Beck A. Staying well during pregnancy and the postpartum: a pilot randomized trial of mindfulness-based cognitive therapy for the prevention of depressive relapse/recurrence. J Consult Clin Psychol. 2016;84(2):134-145. doi:10.1037/ccp0000068
30. Heh SS, Fu YY. Effectiveness of informational support in reducing the severity of postnatal depression in Taiwan. J Adv Nurs. 2003;42(1):30-36. doi:10.1046/j.1365-2648.2003.02576.
31. Dennis CL. The effect of peer support on postpartum depression: a pilot randomized controlled trial. Can J Psychiatry. 2003;48(2):115-124. doi:10.1177/070674370304800209
32. Dennis CL, Hodnett E, Kenton L, et al. Effect of peer support on prevention of postnatal depression among high risk women: multisite randomised controlled trial. BMJ. 2009;338:a3064. doi:10.1136/bmj.a3064
33. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001;62(2):82-86. doi:10.4088/JCP.v62n0202
34. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004;161(7):1290-1292. doi:10.1176/appi.ajp.161.7.1290
35. Mozurkewich EL, Clinton CM, Chilimigras JL, et al. The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial. Am J Obstet Gynecol. 2013;208(4):313.e1-313.e9. doi:10.1016/j.ajog.2013.01.038
36. Werner EA, Gustafsson HC, Lee S, et al. PREPP: postpartum depression prevention through the mother-infant dyad. Arch Women Ment Health. 2016;19(2):229-242. doi:10.1007/s00737-015-0549-5
37. Zlotnick C, Johnson SL, Miller IW, Pearlstein T, Howard M. Postpartum depression in women receiving public assistance: pilot study of an interpersonal-therapy-oriented group intervention. Am J Psychiatry. 2001;158(4):638-640. doi:10.1176/appi.ajp.158.4.638
38. Zlotnick C, Miller IW, Pearlstein T, Howard M, Sweeney P. A preventive intervention for pregnant women on public assistance at risk for postpartum depression. Am J Psychiatry. 2006;163(8):1443-1445. doi:10.1176/ajp.2006.163.8.1443
39. Zlotnick C, Capezza NM, Parker D. An interpersonally based intervention for low-income pregnant women with intimate partner violence: a pilot study. Arch Womens Ment Health. 2011;14(1):55-65. doi:10.1007/s00737-010-0195-x
40. Zlotnick C, Tzilos G, Miller I, Seifer R, Stout R. Randomized controlled trial to prevent postpartum depression in mothers on public assistance. J Affect Disord. 2016;189:263-268. doi:10.1016/j.jad.2015.09.059
41. Howell EA, Balbierz A, Wang J, Parides M, Zlotnick C, Leventhal H. Reducing postpartum depressive symptoms among black and Latina mothers: a randomized controlled trial. Obstet Gynecol. 2012;119(5):942-949. doi:10.1097/AOG.0b013e318250ba48
42. Ortiz Collado MA, Saez M, Favrod J, Hatem M. Antenatal psychosomatic programming to reduce postpartum depression risk and improve childbirth outcomes: a randomized controlled trial in Spain and France. BMC Pregnancy Childbirth. 2014;14:22. doi:10.1186/1471-2393-14-22
43. Dugravier R, Tubach F, Saias T, et al; CAPEDP Study Group. Impact of a manualized multifocal perinatal home-visiting program using psychologists on postnatal depression: the CAPEDP randomized controlled trial. PLoS One. 2013;8(8):e72216. doi:10.1371/journal.pone.0072216
44. Wiggins M, Oakley A, Roberts I, et al. The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas. Health Technol Assess. 2004;8(32):1-120. doi:10.3310/hta8320
45. Feinberg M, Kan ML. Establishing family foundations: intervention effects on coparenting, parent/infant well-being, and parent-child relations. J Fam Psychol. 2008;22(2):253-263. doi:10.1037/0893-318.104.22.168
46. Woolhouse H, Mercuri K, Judd F, Brown SJ. Antenatal mindfulness intervention to reduce depression, anxiety and stress: a pilot randomised controlled trial of the MindBabyBody program in an Australian tertiary maternity hospital. BMC Pregnancy Childbirth. 2014;14:369. doi:10.1186/s12884-014-0369-z
47. Milgrom J, Schembri C, Ericksen J, Ross J, Gemmill AW. Towards parenthood: an antenatal intervention to reduce depression, anxiety and parenting difficulties. J Affect Disord. 2011;130(3):385-394. doi:10.1016/j.jad.2010.10.045
48. Leung SS, Lam TH. Group antenatal intervention to reduce perinatal stress and depressive symptoms related to intergenerational conflicts: a randomized controlled trial. Int J Nurs Stud. 2012;49(11):1391-1402. doi:10.1016/j.ijnurstu.2012.06.014
49. Cooper PJ, De Pascalis L, Woolgar M, Romaniuk H, Murray L. Attempting to prevent postnatal depression by targeting the mother-infant relationship: a randomised controlled trial. Prim Health Care Res Dev. 2015;16(4):383-397. doi:10.1017/S1463423614000401
50. Kozinszky Z, Dudas RB, Devosa I, et al. Can a brief antepartum preventive group intervention help reduce postpartum depressive symptomatology? Psychother Psychosom. 2012;81(2):98-107. doi:10.1159/000330035
51. Brugha TS, Morrell CJ, Slade P, Walters SJ. Universal prevention of depression in women postnatally: cluster randomized trial evidence in primary care. Psychol Med. 2011;41(4):739-748. doi:10.1017/S00332917100014
52. Norman E, Sherburn M, Osborne RH, Galea MP. An exercise and education program improves well-being of new mothers: a randomized controlled trial. Phys Ther. 2010;90(3):348-355. doi:10.2522/ptj.20090139
53. Perales M, Refoyo I, Coteron J, Bacchi M, Barakat R. Exercise during pregnancy attenuates prenatal depression: a randomized controlled trial. Eval Health Prof. 2015;38(1):59-72. doi:10.1177/0163278714533566
54. Songøygard KM, Stafne SN, Evensen KA, Salvesen KÅ, Vik T, Mørkved S. Does exercise during pregnancy prevent postnatal depression? a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(1):62-67. doi:10.1111/j.1600-0412.2011.01262.x
55. Hayes BA, Muller R, Bradley BS. Perinatal depression: a randomized controlled trial of an antenatal education intervention for primiparas. Birth. 2001;28(1):28-35. doi:10.1046/j.1523-536x.2001.00028.x
56. Howell EA, Bodnar-Deren S, Balbierz A, et al. An intervention to reduce postpartum depressive symptoms: a randomized controlled trial. Arch Womens Ment Health. 2014;17(1):57-63. doi:10.1007/s00737-013-0381-8
57. Maimburg RD, Vaeth M. Postpartum depression among first-time mothers—results from a parallel randomised trial. Sex Reprod Healthc. 2015;6(2):95-100. doi:10.1016/j.srhc.2015.01.003
58. Reid M, Glazener C, Murray GD, Taylor GS. A two-centred pragmatic randomised controlled trial of two interventions of postnatal support. BJOG. 2002;109(10):1164-1170. doi:10.1111/j.1471-0528.2002.01306.x
59. Stamp GE, Williams AS, Crowther CA. Evaluation of antenatal and postnatal support to overcome postnatal depression: a randomized, controlled trial. Birth. 1995;22(3):138-143. doi:10.1111/j.1523-536X.1995.tb00689.x
60. Hiscock H, Cook F, Bayer J, et al. Preventing early infant sleep and crying problems and postnatal depression: a randomized trial. Pediatrics. 2014;133(2):e346-354. doi:10.1542/peds.2013-1886
61. Hiscock H, Wake M. Randomised controlled trial of behavioural infant sleep intervention to improve infant sleep and maternal mood. BMJ. 2002;324(7345):1062-1065. doi:10.1136/bmj.324.7345.1062
62. Priest SR, Henderson J, Evans SF, Hagan R. Stress debriefing after childbirth: a randomised controlled trial. Med J Aust. 2003;178(11):542-545.
63. Blasio PD, Camisasca E, Caravita SC, Ionio C, Milani L, Valtolina GG. The effects of expressive writing on postpartum depression and posttraumatic stress symptoms. Psychol Rep. 2015;117(3):856-882. doi:10.2466/02.13.PR0.117c29z3
64. Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC, Heird WC. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol. 2003;188(5):1348-1353. doi:10.1067/mob.2003.275
65. Fontein-Kuipers YJ, Ausems M, de Vries R, Nieuwenhuijze MJ. The effect of Wazzup Mama?! an antenatal intervention to prevent or reduce maternal distress in pregnancy. Arch Women Ment Health. 2016;19(5):779-788. doi:10.1007/s00737-016-0614-8
66. Cohen J. A power primer. Psychol Bull. 1992;112 (1):155-159. doi:10.1037/0033-2909.112.1.155
67. Gartlehner G, Hansen RA, Reichenpfader U, et al. Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report. Portland: Oregon Health & Science University; 2011.
68. O’Connor EA, Whitlock EP, Beil TL, Gaynes BN. Screening for depression in adult patients in primary care settings: a systematic evidence review. Ann Intern Med. 2009;151(11):793-803. doi:10.7326/0003-4819-151-11-200912010-00007
69. Alwan S, Friedman JM, Chambers C. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs. 2016;30(6):499-515. doi:10.1007/s40263-016-0338-3
70. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70(4):436-443. doi:10.1001/jamapsychiatry.2013.684
71. Molenaar NM, Brouwer ME, Duvekot JJ, et al. Antidepressants during pregnancy: guideline adherence and current practice amongst Dutch gynaecologists and midwives. Midwifery. 2018;61:29-35. doi:10.1016/j.midw.2018.02.018
72. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066
73. Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database Syst Rev. 2013;2(2):CD001134.
74. Sockol LE, Epperson CN, Barber JP. Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev. 2013;33(8):1205-1217. doi:10.1016/j.cpr.2013.10.004
75. Jardri R, Pelta J, Maron M, et al. Predictive validation study of the Edinburgh Postnatal Depression Scale in the first week after delivery and risk analysis for postnatal depression. J Affect Disord. 2006;93(1-3):169-176. doi:10.1016/j.jad.2006.03.009
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an analytic framework to visually display the key questions that the review will address to allow the USPSTF to evaluate the effectiveness and safety of a preventive service. The questions are depicted by linkages that relate interventions and outcomes. Refer to the USPSTF Procedure Manual for interpretation of the analytic framework.14 HrQoL indicates health-related quality of life.
KQ indicates key question.
a Reasons for exclusion: Aim: Study aim was not relevant. Setting: Study was not conducted in a country relevant to US practice, or not conducted in, recruited from, or feasible for primary care or a health system. Comparative effectiveness: Active comparator (eg, liquid-based cytology vs conventional cytology alone). Outcomes: Study did not have relevant outcomes or had incomplete outcomes. Population: Study was not conducted in an included population. Intervention: Intervention was out of scope. Design: Study did not use an included design. Language: Publication not in English. Quality: Study was poor quality. Unable to locate: Review staff was unable to locate article.
b Studies may appear in more than 1 KQ.
Weights are from random-effects analysis. BDI-II indicates Beck Depression Inventory II; CBT, cognitive-behavioral therapy; EPDS, Edinburgh Postnatal Depression Scale; IPT, interpersonal therapy; LQ, Leverton Questionnaire; MT, motivational therapy; NR, not reported; RR, risk ratio.
a ”g” indicates during gestation and “p” indicates postpartum; thus, for example, g37 indicates 37 weeks’ gestation and p12 indicates 12 weeks postpartum.
b Study-reported adjusted analysis was not statistically significant, although effect size shown in the forest plot, based on unadjusted data, is statistically significant. Tourne indicates a psychosomatic humanist group intervention developed by Dr Claude-Emile Tourne.
Weights are from random-effects analysis. BDI-II indicates Beck Depression Inventory II; CES-D, Center for Epidemiologic Studies Depression Scale; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EPDS, Edinburgh Postnatal Depression Scale; NR, not reported; PA, physical activity; PPD, postpartum depression; RR, risk ratio.
a ”g” indicates during gestation and “p” indicates postpartum; thus, for example, g37 indicates 37 weeks’ gestation and p12 indicates 12 weeks postpartum.
b Study-reported adjusted analyses were statistically significant, although effect size shown in the forest plot, based on unadjusted data, are not statistically significant.
|Intervention Category||No. of Studies
(No. of Participants)
|No. of Studies (%)|
in the United States
|Overall||50 (22,385)||8 (16)||20 (40)||26 (52)||42 (84)||42 (84)||12 (24)||23 (46)||20 (40)||11 (22)||13 (26)|
|Counseling||20 (4107)||2 (10)||12 (60)||17 (85)||17 (85)||17 (85)||6 (30)||5 (25)||13 (65)||8 (40)||10 (50)|
|Health system||3 (5321)||0||0||1 (33.3)||2 (66.7)||3 (100)||0||3 (100)||1 (33.3)||0||0|
|Physical activity||3 (1200)||1 (33.3)||0||2 (66.7)||3 (100)||3 (100)||0||3 (100)||0||0||0|
|Education||6 (2949)||2 (33.3)||2 (33.3)||2 (33.3)||5 (83.3)||6 (100)||1 (16.7)||5 (83.3)||1 (16.7)||2 (33.3)||1 (16.7)|
|Support||7 (4569)||2 (28.6)||0||2 (28.6)||5 (71.4)||7 (100)||2 (28.6)||3 (42.9)||2 (28.6)||0||2 (28.6)|
|Sleep||3 (980)||0||1 (33.3)||0||3 (100)||2 (66.7)||0||1 (33.3)||0||1 (33.3)||0|
|Debriefing||2 (2786)||0||0||0||1 (50)||2 (100)||0||1 (50)||0||0||0|
|Expressive writing||1 (120)||0||0||0||1 (100)||1 (100)||0||1 (100)||0||0||0|
|Yoga||1 (46)||0||1 (100)||1 (100)||1 (100)||0||0||0||0||0||0|
|Antidepressants||2 (80)||0||2 (100)||0||2 (100)||1 (50)||2 (100)||0||2 (100)||0||0|
|Omega-3 fatty acids||2 (227)||1 (50)||2 (100)||1 (50)||2 (100)||0||1 (50)||1 (50)||1 (50)||0||0|
Abbreviation: SES, socioeconomic status.
a Number recruited via screening or outreach vs volunteer opt-in.
b Studies excluded persons with a diagnosis of depressive disorder or who met an a priori threshold for symptoms of depression (eg, exceeded a specified score on a screening test).
|Counseling Approach||No. of Studies
|Pooled RR (95% CI)||I2, %||τ2|
|All counseling trials||17 (3094)||0.61 (0.47-0.78)||39||0.09|
|CBT||8 (2128)||0.51 (0.33-0.79)||49||0.17|
|CBT Moms and Babies Program||4 (325)||0.47 (0.26-0.84)||0||0.0|
|IPT||8 (2095)||0.71 (0.50-1.00)||42||0.09|
|IPT ROSE program||5 (464)||0.50 (0.32-0.80)||12||0.04|
|All counseling trials, limited to trials targeting women at increased risk of perinatal depression||14 (1411)||0.55 (0.44-0.68)||0||0.0|
Abbreviations: CBT, cognitive behavioral therapy; IPT, interpersonal therapy; ROSE, Reach Out, Stand Strong, Essentials for New Mothers; RR, risk ratio.
|Intervention||No. of Studies
(No. of Observations)
|Summary of Findings||Consistency and Precision||Other Limitations||Strength of
|KQ1: Benefits of Interventions to Prevent Perinatal Depression|
|Counseling||20 (4107)||Counseling interventions reduced the risk of perinatal depression, primarily using cognitive behavioral therapy and interpersonal therapy
In pooled analyses, the likelihood of perinatal depression was 39% lower in intervention than control participants (pooled RR, 0.61 [95% CI, 0.47 to 0.78]; 17 trials [n = 3094]; I2 = 39%)
Depression symptom severity was reduced by 1.5 points more in intervention than control participants (WMD, −1.51 [95% CI, −2.84 to −0.18]; 13 trials [n = 1367]; I2 = 61%; T2 = 2.9)
|Reasonably consistent, reasonably precise||Small-studies effect suggests possible overestimate of effect size, many small trials, only 2 good-quality trials
Dichotomous depression outcomes are a mix of incidence, prevalence, and being above a severity cutoff
|Moderate||60% conducted in the United States, most targeting women at increased risk of PND, most initiating the intervention during
Interventions are not widely available and require specialized training
|Health system||3 (5321)||All 3 health system interventions reduced the risk of perinatal depression by 29% to 69%, although the pooled effect was not statically significant (REML RR, 0.58 [95% CI, 0.22 to 1.53]; 3 studies [n = 4738]; I2 = 66.3%)
One study each reported improvements in anxiety and SF-36 mental health component scores, but the third found no difference in SF-36 score
|Reasonably consistent, imprecise||One study reported results only for the subset of women who had not developed elevated symptoms by 6 weeks postpartum; no good-quality studies
One study was a nonrandomized controlled intervention study
|Low||Problematic: all conducted outside the United States in health care systems very different from the United States (eg, postpartum home visitors are part of usual care)|
|Physical activity||3 (1200)||One of the physical activity trials demonstrated a statistical significant reduction in the risk of perinatal depression, with 12.2% of intervention participants exceeding an EPDS threshold vs 24.7% of control participants
Absolute risk differences were smaller and not statistically significant in the other trials
|Reasonably consistent, imprecise||Small body of evidence; only 1 study showed statistically significant between-group differences||Insufficient||None conducted in the United States, only included unselected populations; however, studies included both pregnant and postpartum women|
|Education||6 (2949)||Most trials did not find a benefit; however, 1 of the 2 US-based trials found a promising short-term benefit of a brief PND education session in the hospital after delivery, with 1 brief follow-up telephone call (6.3% of intervention participants had EPDS scores ≥10, vs 11.4% of controls; adjusted OR, 0.45 [95% CI, 0.21 to 0.92])
Effect size was smaller and not statistically significant on replication
|Wide variety of approaches, minimal replication or similar interventions; the 1 replicated intervention had mixed findings||Insufficient||Only 2 trials of the same intervention were conducted in the United States|
|Supportive interventions||7 (4569)||Three trials showed benefits of treatment, although effects were either not large, of marginal statistical significance, or based on a very small sample
Telephone-based support by trained peers with history of PND showed most promise
|Inconsistent, imprecise||Wide variety of approaches with minimal replication; adherence was very low in 1 of 2 nondirective support group interventions||Insufficient||None conducted in the United States, some embedded in health care systems with very low applicability to the United States|
|Sleep||3 (980)||Mixed results, but some promising findings, including a 43% reduction in the odds of PND in 1 study (adjusted OR, 0.57 [95% CI, 0.34 to 0.94])||Inconsistent, imprecise||Few studies, no good-quality studies||Insufficient||Only 1 small trial conducted in the United States (n = 54); targeted both early and later postpartum phases|
|Yoga||1 (46)||No statistically significant or potentially clinically important differences between groups in depression severity (mean difference in change in depression symptoms at posttest, 0.1 [95% CI, −3.2 to 3.5]) or anxiety||Consistency NA, imprecise||Single small fair-quality study||Insufficient||Conducted in the United States, among women with elevated anxiety and depressive symptoms|
|Debriefing||2 (2786)||No benefit of debriefing the birth experience (pooled RR, 1.04 [95% CI, 0.88 to 1.22]; 2 trials [n = 2662]; I2 = 27%)||Reasonably consistent, reasonably precise||Only 2 fair-quality trials||Low||Neither conducted in the United States|
|Expressive writing||1 (120)||Expressive writing not clearly associated with PND risk in single relatively small study (RR, 0.55 [95% CI, 0.20 to 1.53])||Consistency NA, imprecise||Single fair-quality small study||Insufficient||Not conducted in the United States|
|Antidepressants||Sertraline: 1 (22)
Nortriptyline: 1 (58)
|Sertraline may reduce the risk of PND, but nortriptyline is unlikely to reduce the risk of PND||Consistency NA, imprecise||Single very small fair-quality study for each agent||Insufficient||Conducted in the United States; recruitment through health care setting, women with a history of PND|
|Omega-3 fatty acids||2 (227)||Supplementation with omega-3 fatty acids (DHA, EPA) is not associated with a reduced likelihood of PND (pooled RR, 1.71 [95% CI, 0.70 to 4.17]; 2 trials [n = 204]; I2 = 0%)||Reasonably consistent, reasonably precise||Only 2 trials (1 good quality)||Low||Both US-based, unselected and at-risk populations, including pregnant and postpartum women|
|KQ2: Harms of Interventions to Prevent Perinatal Depression|
|Behavior-based||0||Adverse events were not reported in behavior-based trials, but other outcomes consistently trended in direction of benefit or no effect||Consistency NA, imprecise||No studies directly reported on harms||Low|
|Omega-3 fatty acids||1 (126)||No adverse events were reported in either treatment group||Consistency NA, imprecise||Low (DHA)|
|Nortriptyline||1 (58)||Nortriptyline was associated with constipation (78% vs 22%), but there were no differences in withdrawal because of adverse effects; 1 patient taking nortriptyline converted to mania (vs none taking placebo)||Consistency NA, imprecise||Underpowered to detect serious adverse events such as conversion to mania||Insufficient||Conducted in the United States|
|Sertraline||1 (22)||Sertraline with associated with an increased risk of dizziness (57% vs 13%) and drowsiness (100% vs 50%); 3 patients taking sertraline withdrew because of adverse effect (vs none taking placebo); 1 patient taking sertraline converted to mania (vs none taking placebo)||Consistency NA, imprecise||Underpowered to detect serious adverse events such as conversion to mania||Insufficient||Conducted in the United States|
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EPDS, Edinburgh Postnatal Depression Scale; KQ, key question; NA, not applicable; OR, odds ratio; PND, perinatal depression; REML, restricted maximum likelihood model; RR, risk ratio; SES, socioeconomic status; SF-36, 36-Item Short Form Health Survey; WMD, weighted mean difference.